Will the FDA approve Zenas BioPharma's obexelimab for treatment of Immunoglobulin G4-Related Disease by June 10, 2027?
deadline 2027-06-10
confidence medium
tier 4 evidence
86%PolySignal estimate
Resolution criterion
Yes if the FDA approves obexelimab for the indication stated above (Drugs@FDA entry, FDA announcement or Zenas BioPharma press release) no later than June 10, 2027. A complete response letter, an extension of the PDUFA date or the absence of a decision by then counts as no. An accelerated or conditional approval counts as an approval; a later label update does not change the outcome.
Verified starting state
As of October 9, 2026: according to the Zenas BioPharma filing of August 13, 2026, the FDA has set a PDUFA target action date of May 27, 2027. Source: https://www.sec.gov/Archives/edgar/data/1953926/000110465926095437/tm2622871d1_ex99-1.htm
What pushes it up
- FDA has set a PDUFA target action date of May 27 2027, which is before the June 10 2027 deadline, indicating the agency expects to complete review by then [tier 1]
- The application has been formally filed and accepted, moving it into the review stage where approval odds are generally higher than the overall NME base rate [tier 1]
What pushes it down
- PDUFA target dates are not guarantees; a subset of applications receive extensions or complete response letters that would push approval past the deadline [tier 1]
- All publicly available articles are tier 4 and only announce filing or data, providing no concrete evidence of approval [tier 4]
What would move this number most
Whether the FDA will meet the May 27 2027 PDUFA target date or issue a complete response letter/extension
How this number is built
| Deadline | 2027-06-10 |
| Base rate | 87% |
| Best evidence | tier 4 · 0 article(s) used |
| Independent runs | 82 · 90 (spread 8 pts) |
| Confidence | medium |
| Evidence cap | not triggered |
| Last revised | 2026-10-09 21:35 |
| Model | openai/gpt-oss-120b (Groq) |